Werewolf Therapeutics (HOWL) to Post Quarterly Earnings on Thursday

Werewolf Therapeutics (NASDAQ:HOWL) will likely be issuing its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Werewolf Therapeutics to announce earnings of ($0.28) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Friday, July 31, 2026 at 7:00 AM ET.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings data on Friday, July 31st. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.36. The firm had revenue of $21.00 million for the quarter, compared to the consensus estimate of $21.00 million. On average, analysts expect Werewolf Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Werewolf Therapeutics Price Performance

Shares of HOWL stock opened at $0.38 on Tuesday. The stock has a market cap of $18.57 million, a P/E ratio of -0.50 and a beta of 0.29. Werewolf Therapeutics has a one year low of $0.27 and a one year high of $2.38. The stock has a fifty day moving average price of $0.38 and a 200 day moving average price of $0.59.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Wall Street Zen raised shares of Werewolf Therapeutics to a “sell” rating in a report on Saturday, August 1st. Weiss Ratings lowered shares of Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 16th. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $3.75.

Insider Buying and Selling at Werewolf Therapeutics

In other Werewolf Therapeutics news, Director Luke Evnin sold 107,429 shares of the business’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $0.31, for a total value of $33,302.99. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Ra Capital Management, L.P. sold 416,911 shares of the firm’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $0.35, for a total value of $145,918.85. Following the sale, the insider directly owned 303,719 shares in the company, valued at approximately $106,301.65. This represents a 57.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 2,513,385 shares of company stock worth $982,239 in the last ninety days. 23.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Werewolf Therapeutics

Several institutional investors have recently bought and sold shares of the company. Regal Investment Advisors LLC boosted its holdings in Werewolf Therapeutics by 93.3% during the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after purchasing an additional 25,389 shares during the last quarter. Vontobel Holding Ltd. increased its holdings in Werewolf Therapeutics by 66.7% during the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after buying an additional 24,003 shares during the last quarter. Qube Research & Technologies Ltd acquired a new position in Werewolf Therapeutics during the second quarter worth $48,000. AQR Capital Management LLC bought a new stake in Werewolf Therapeutics during the first quarter worth $79,000. Finally, Bridgeway Capital Management LLC lifted its stake in Werewolf Therapeutics by 157.7% in the second quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock valued at $111,000 after acquiring an additional 62,414 shares during the last quarter. Institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.